Peer-reviewed study in the Journal of the American College of Cardiology – Heart Failure
N = 245
56% reduction in 30-day readmissions
82% reduction in 30-day mortality
86% reduction in 365-day mortality
62% identified as anemic
In a peer-reviewed study, BVA performed on admission results in a
2.6 days reduction in length of stay.
“Blood volume analysis offers providers a unique opportunity to reduce heart failure readmissions and mortality in both the HFpEF and HFrEF populations. We have used the technology at our center extensively and have found it to be hugely informative and cost-effective.“
John Jefferies M.D., MPH, FACC, FAHA, FAAP, FHFSA, FRCPE
Chen J, Normand S-LT, Wang Y, et al. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries: 1998-2008. J Am Med Assoc 2011;306:1669-78.
Heidenreich et al. Forecasting the Future of Cardiovascular Disease in the United States. A Policy Statement from the American Heart Association. Circulation. 2011;123:933-944.
2013 ACCF/AHA Guideline for the Management of Heart Failure, JACC Vol. 62, No. 16, 2013.
As the pioneer in blood volume analysis, Daxor provides education and the resources needed to ensure easy onboarding along with continuing support to drive maximum value from your BVA system throughout your facility. With a long-standing commitment to improving care and numerous studies validating our technology, Daxor is completely focused on advancing healthcare by enabling optimal fluid management with blood volume analysis. Our vision is optimal blood volume for all.
Call us at 865-425-0555.
Daxor Corporation is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for use in a broad range of medical and surgical conditions.